PIERLUIGI BERTORA

Assistant professor

Università degli Studi di Torino
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Pierluigi Bertora is an Assistant Professor at the Università degli Studi di Milano, Italy. His research focuses on cognitive impairment in stroke patients, exploring its association with neuropsychiatric and functional features. He has contributed to studies on the predictive value of neuropsychological tests in the context of cerebrovascular diseases.

Articles (4)

BACKGROUND: Some patients with stroke have prestroke cognitive impairment (pre-SCI), but its etiology is not clear. The aim of this cross-sectional study was to assess the frequency of pre-SCI and its association with premorbid neuropsychiatric, functional, and neuroimaging features. METHODS: Patients hospitalized in stroke unit with an informant who could complete IQCODE (Informant Questionnaire for Cognitive Decline in the Elderly) were included. Pre-SCI was diagnosed if the IQCODE score was >3.3. Prestroke assessment also included NPI-Q (Neuropsychiatric Inventory Questionnaire), the basic Activities of Daily Living and Instrumental Activities of Daily Living scales, and the Clinical Dementia Rating scale. A multivariate logistic regression model was used to evaluate the association of pre-SCI with age, sex, education, arterial hypertension, atrial fibrillation, white matter lesions, cerebral microbleeds, and pathological medial temporal lobe atrophy. RESULTS: IQCODE was available in 474 of 520 patients (91.2%; 45% women; mean age 75.5±13.3 years). Pre-SCI had a prevalence of 32.5% and was associated with prestroke NPI-Q (pre-SCI absent versus present, 1.7±2.3 versus 5.5±4.9; P <0.001), Activities of Daily Living scale (0.3±0.8 versus 1.8±1.9; P <0.001), Instrumental Activities of Daily Living scale (0.6±1.3 versus 3.8±4.0; P <0.001), and Clinical Dementia Rating scale score (0.7±1.7 versus 7.2±6.2; P <0.001). In the 271 patients with a magnetic resonance imaging available, the multivariate logistic regression showed that age (odds ratio [OR], 1.05 [95% CI, 1.62–9.73]), white matter lesions (OR, 1.26 [95% CI, 1.003–1.58]), and a pathological medial temporal lobe atrophy score (OR, 3.97 [95% CI, 1.62–9.73]) were independently associated with pre-SCI. In the 218 patients with ischemic stroke, white matter lesions (OR, 1.34 [95% CI, 1.04–1.72]) and medial temporal lobe atrophy (OR, 3.56 [95% CI, 1.38–9.19]), but not age, were associated with pre-SCI. CONCLUSIONS: One-third of patients admitted to a stroke unit have pre-SCI that is associated with preexisting neuropsychiatric symptoms and functional performance. White matter lesions and medial temporal lobe atrophy are associated with pre-SCI, suggesting that both small vessel disease and neurodegeneration might be involved in its etiology.

Year:

2024

Background The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF. Methods We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately. Results A total of 1.742 patients were included (46% male), and 898 (52%) received statins after the index event. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97 - 0.99, p = 0.001), male sex (OR 1.35, 95% CI 1.07 - 1.70, p = 0.013), anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, p <0.0001), hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, p <0.0001), paroxysmal AF (OR 1.40, 95% CI 1.12 - 1.75, p = 0.003), leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, p = 0.004) and heart failure (OR 0.72, 95% CI 0.53 - 0.98, p = 0.034). Statin use was not associated with the combined outcome event (OR 0,81, 95% CI 0,56 – 1,19, p = 0.286) and ischemic outcome event (OR 1,13, 95% CI 0,71 – 1,82, p = 0.604) while was associated with a lower risk of hemorrhagic outcome event (OR 0,49, 95% CI 0,27 – 0,88, p = 0.016). Conclusions Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.

Year:

2024

Year:

2022

Year:

2020

Collaborators (36)

Simona Sacco

Full Professor of Neurology - Head of the Clinical Neurology Unit

University of L'Aquila

ITALY
View details

Danilo Toni

Full Professor of Neurology

Sapienza University

ITALY
View details

Alessandro Pezzini

Associate Professor of Neurology

University of Parma

ITALY
View details

Walter Ageno

Associate Professor

University of Insubria

ITALY
View details

Davide Strambo

-

SWITZERLAND
View details

George Ntaios

Professor of Internal Medicine

University of Thessaly

GREECE
View details

Sung Il Sohn

Professor

Keimyung University Dongsan Medical Center

SOUTH KOREA
View details

Theodoros Karapanayiotides

Associate Professor

Aristotle University of Thessaloniki

GREECE
View details

Georgios Tsivgoulis

-

UNITED STATES
View details

Piergiorgio Lochner

Head of Neurointensive Care Unit Unit and Neurosonology Lab

Saarland University

GERMANY
View details

Patrik Michel

Associate Professor

Lausanne University Hospital

SWITZERLAND
View details

Eugenia Rota

Chief

-

ITALY
View details

Jukka Putaala

-

FINLAND
View details

Maria Kosmidou

Ass Professor

Aristotle University of Thessaloniki

GREECE
View details

Brian Mac Grory

Assistant Professor

Duke University School of Medicine

UNITED STATES
View details

Azmil H Abdul-Rahim

University of Glasgow

UNITED KINGDOM
View details

Gian Marco De Marchis

Head of Personal Board

University Hospital Basel

SWITZERLAND
View details

MARINA DIOMEDI

Associate Professor, Tor Vergata University

University of Rome Tor Vergata

ITALY
View details

Laetitia Yperzeele

Antwerp University Hospital

BELGIUM
View details

Leonardo Pantoni

-

ITALY
View details

Stefan Engelter

Chair Department Rehabilitation & Neurology and Head of Stroke Treatment Pathyway

-

SWITZERLAND
View details

Sotirios Giannopoulos

Professor fo Neurology

National and Kapodistrian University of Athens

GREECE
View details

Lina Palaiodimou

National and Kapodistrian University of Athens

GREECE
View details

Jesse Dawson

Professor of Stroke Medicine

University of Glasgow

UNITED KINGDOM
View details

Yuriy Flomin

Professor

ukraine; shupyk national healthcare university of ukraine

UKRAINE
View details

Turgut Tatlisumak

Professor

Göteborgs Universitet

SWEDEN
View details

Isabella Canavero

Fondazione IRCCS Istituto Neurologico Carlo Besta

ITALY
View details

Daniel Strbian

-

FINLAND
View details

PANAGIOTIS HALVATSIOTIS

Associate Professor

National and Kapodistrian University of Athens - Faculty of Medicine

GREECE
View details

Maurizio Paciaroni

Docenti di ruolo di IIa fascia

University of Ferrara

ITALY
View details

Konstantinos Vadikolias

Professor

Democritus University of Thrace

GREECE
View details

Maurizio Acampa

University of Siena

ITALY
View details

David Seiffge

-

SWITZERLAND
View details

Andrea Morotti

-

ITALY
View details

Alexandros Polymeris

Attending Neurologist

University Hospital Basel

SWITZERLAND
View details

Manuel Cappellari

-

ITALY
View details